As of June 30, 2026, Enanta Pharmaceuticals, Inc. carries a market capitalization of 369.82M, placing it among publicly traded companies globally. Its enterprise value stands at 252.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 369.82M |
| Enterprise Value | 252.67M |
Enanta Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.
| Earnings Date | 11/16/2026 |
As of June 30, 2026, Enanta Pharmaceuticals, Inc. has 29.12M shares outstanding.
| Shares Outstanding | 29.12M |
These figures are as of June 30, 2026. The price-to-sales ratio is 6.02, and the price-to-book ratio stands at 4.18.
| PS Ratio | 6.02 |
| PB Ratio | 4.18 |
| P/TBV Ratio | 4.18 |
| P/FCF Ratio | -10.63 |
| P/OCF Ratio | -11.12 |
These figures are as of June 30, 2026. The EV/Sales ratio of 4.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 252.67M versus a market cap of 369.82M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 4.42 |
As of June 30, 2026, Enanta Pharmaceuticals, Inc. maintains a current ratio of 3.76, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.07, indicating elevated leverage, while an interest coverage ratio of -4.17 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.76 |
| Quick Ratio | 3.62 |
| Debt / Equity | 55.07 |
| Debt / EBITDA | -1.03 |
| Interest Coverage | -4.17 |
Over the twelve months ended June 30, 2026, Enanta Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -70.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.15, reflecting losses generated across the asset base. The company generates approximately 476,002.73 in revenue per employee across its workforce of 120.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -70.12 |
| Return on Assets (ROA) | -21.15 |
| Revenue Per Employee | 476,002.73 |
| Employee Count | 120.00 |
Over the twelve months ended June 30, 2026, Enanta Pharmaceuticals, Inc. recorded 86,654.70 in income tax expense. The company reported a pretax loss of -55.26M and -55.35M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 86,654.70 |
As of the close on November 17, 2026, Enanta Pharmaceuticals, Inc.'s stock has declined approximately 12.39% over the past 52 weeks. The 50-day moving average sits at 10.49, while the 200-day moving average is 11.36.
| 52-Week Price Change | -12.39% |
| 50-Day Moving Average | 10.49 |
| 200-Day Moving Average | 11.36 |
Over the twelve months ended June 30, 2026, Enanta Pharmaceuticals, Inc. generated 57.12M in revenue and converted that into -55.35M in net income, yielding earnings per share of -2.04. EBITDA reached -47.11M, while operating income came in at -51.40M.
| Revenue | 57.12M |
| Operating Income | -51.40M |
| Pretax Income | -55.26M |
| Net Income | -55.35M |
| EBITDA | -47.11M |
| EBIT | -51.40M |
| Earnings Per Share (EPS) | -2.04 |
As of June 30, 2026, Enanta Pharmaceuticals, Inc. holds 165.87M in cash and equivalents against 48.72M in total debt, resulting in a net debt position of -29.25M. Total book value stands at 88.46M, with working capital of 130.82M providing operational flexibility.
| Cash & Cash Equivalents | 165.87M |
| Total Debt | 48.72M |
| Net Debt | -29.25M |
| Equity (Book Value) | 88.46M |
| Book Value Per Share | 3.04 |
| Working Capital | 130.82M |
Enanta Pharmaceuticals, Inc. produced -30.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.42M in capital expenditures, free cash flow totaled -32.33M - equivalent to -1.19 per share.
| Operating Cash Flow | -30.91M |
| Capital Expenditures | -1.42M |
| Free Cash Flow | -32.33M |
| FCF Per Share | -1.19 |
These figures cover the twelve months ended June 30, 2026. The operating margin of -89.99 and net profit margin of -96.89 provide insight into operational efficiency.
| Operating Margin | -89.99 |
| Pretax Margin | -96.74 |
| Profit Margin | -96.89 |
| EBITDA Margin | -82.47 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.17, meaning Enanta Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -10.17 |
| FCF Yield | -9.41 |
As of June 30, 2026, Enanta Pharmaceuticals, Inc. has an Altman Z-Score of -0.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.65 |